Imatinib Stada (Imatinib)

Imatinib acts on BCR‑ABL, c‑KIT and PDGFR driven malignancies, providing targeted therapy for several cancer types.

• Chronic myeloid leukemia: suppresses leukemic cell proliferation and induces remission.
• Gastrointestinal stromal tumor: inhibits tumor growth by blocking c‑KIT signaling.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia: achieves molecular remission by targeting BCR‑ABL.
• Dermatofibrosarcoma protuberans: reduces tumor burden through PDGFR inhibition.

• Imatinib selectively inhibits the ATP‑binding sites of BCR‑ABL, c‑KIT and platelet‑derived growth factor receptors (PDGFR). By blocking these tyrosine kinases, the drug prevents downstream phosphorylation cascades that drive uncontrolled cell division, survival and angiogenesis, leading to apoptosis of malignant cells and tumor growth arrest.

Imatinib may cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any new symptoms.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the lower limbs.
• Fatigue: generalized tiredness affecting daily activities.
• Diarrhea: loose stools that may require fluid replacement.

Serious or Rare Side Effects

• Neutropenia: significant drop in white blood cells, increasing infection risk.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Cardiac failure: reduced heart function, especially in patients with pre‑existing disease.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Pulmonary hypertension: elevated pressure in lung arteries causing breathlessness.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks.

• Blood count monitoring: perform complete blood counts regularly to detect cytopenias.
• Liver function tests: check hepatic enzymes before and during treatment.
• Cardiac assessment: evaluate cardiac history and monitor for signs of heart failure.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh risks; discuss contraception.
• Hypersensitivity: discontinue if severe allergic reactions occur.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase imatinib plasma levels.
• Strong CYP3A4 inducers (e.g., rifampin): reduce therapeutic exposure.
• Antacids containing aluminum or magnesium: may impair absorption.
• Warfarin: potentiates anticoagulant effect, raising INR.
• QT‑prolonging agents: heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CYP3A4 substrates (e.g., midazolam): may require dose adjustment.
• Diuretics (e.g., hydrochlorothiazide): monitor electrolytes and blood pressure.
• Live vaccines: consider timing to avoid reduced vaccine efficacy.